J. Goldman & CO LP Neurocrine Biosciences Inc Transaction History

J. Goldman & CO LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $2.07 Million - $2.27 Million	15,819 Added 79.48%	35,721 $4.92 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $2.6 Million - $2.86 Million	19,902 New	19,902 $2.74 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $516,075 - $642,761	-5,489 Reduced 6.43%	79,885 $8.99 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $6.86 Million - $8.04 Million	76,652 Added 878.84%	85,374 $8.05 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $820,827 - $1.07 Million	8,722 New	8,722 $882,000
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $3.48 Million - $4.08 Million	37,831 Added 498.96%	45,413 $4.82 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $574,639 - $758,730	7,582 New	7,582 $739,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.